1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Acadia Realty Trust reported first-quarter 2026 results and raised its full-year 2026 guidance for FFO As Adjusted to $1.22-$1.26 per share from $1.21-$1.25. Net income attributable to Acadia shareholders was $30.5 million, compared with $1.6 million a year earlier, though NAREIT FFO per share fell to $0.26 from $0.34. The company also corrected several figures in the supplemental report and reported that all eight trustee nominees were elected at its May 13 annual meeting.
Q1 2026 FFO As Adjusted per diluted share was $0.30, up from $0.27 in Q1 2025; NAREIT FFO per diluted share was $0.26, down from $0.34.
2026 guidance raised: FFO As Adjusted to $1.22-$1.26 from $1.21-$1.25; net earnings per share to $0.37-$0.39 from $0.24-$0.26.
Net income attributable to Acadia shareholders was $30.5 million, versus $1.6 million, with a $142.1 million consolidated gain on disposition of properties in the quarter.
At the May 13, 2026 annual meeting, all eight trustees were elected and the non-binding advisory vote on executive compensation received 117,956,235 votes for and 6,293,624 against.
Xtant Medical reported first-quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, and a net loss of $3.1 million, compared with net income of $58,000. The company raised its full-year 2026 revenue guidance to $101 million to $105 million from $95 million to $99 million, citing its exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product. Revenue and profit declined while guidance rose, so the results point in mixed directions for shareholders.
Q1 2026 revenue was $20.9 million versus $32.9 million in Q1 2025, mainly due to the Companion Spine asset sale and 2025 license revenue that did not repeat.
Q1 2026 net loss was $3.1 million versus net income of $58,000; non-GAAP adjusted EBITDA was a loss of $1.6 million versus positive $3.0 million.
2026 revenue guidance raised to $101 million to $105 million from $95 million to $99 million, tied to the Dilon Technologies HEMOBLAST Bellows agreement.
Total indebtedness fell $13.3 million in Q1 2026; cash and cash equivalents were $12.2 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.